HHP 1300 NURS:3138- Exam 4 Medications | University of
Iowa | UPDATED Questions with 100% Verified Answers
Q1: medications used for gallbladder disease
A: ursodeoxycholic acid (UDCA)/chenodeoxycholic acid (chenodiol or CDCA)
mono-octanoin/metyhl tertiary butyl ether
Q2: how long is therapy with ursodeoxycholic
acid/chenodeoxycholic acid require?
A: 6-12 months of therapy required
Q3: MOA for ursodeoxycholic acid/chenodeoxycholic acid
A: reduce the size or dissolve small gallstones
prevents more gallstones from occuring
Q4: what patients are NOT canidates for ursodeoxycholic
acid/chenodeoxycholic acid therapy?
A: with frequent symptoms
cystic duct occlusion
pigment stones
Q5: MOA for mono-octanoin/methyl tertiary butyl ether
A: dissolved gallstones
Q6: how is mono-octanoin administered?
A: infused through percutaneous tube directly into gallbladder
ERCP
Q7: MOA for creon
A: pancreatic enzyme to aid in digestion
Q8: what is creon used as a therapy for?
A: imbalanced nutrition diagnosis for chronic pancreatitis
Q9: role of octredotide/vasopressin for liver failure
A: treatment for decreased cardiac output
Q10: role of rifaximin and lactulose for liver failure
A: ammonia-lowering agents
treatment of hepatic encephalopathy
, Q11: patient education for rifaximin and lactulose
A: want 3 stools per day
avoid GI bleeding
decrease protein
Q12: when giving rifaxamin and lactulose, what do you want to
monitor for?
A: monitor daily ammonia and BMP
to monitor changes in enzymes
Q13: medications used for urinary retention
A: tamsulosin (selective)
terazosin/doxazosin (non-selective)
bethanechol
Q14: medications used for urinary incontinence
A: oxybutynin
tolterodine
Q15: MOA for tamsulosin (selective)
A: blocks alpha1-receptors ONLY IN BLADDER
relaxes smooth muscle in bladder neck and prostate capsule
Q16: MOA for terazosin/doxazosin (non-selective)
A: blocks alpha1-receptors IN WHOLE BODY
relaxes smooth muscle in bladder neck and prostate capsule
Q17: adverse effects for tamsulosin/terazosin/doxazosin
A: MAINLY WITH NON-SELECTIVE
hypotension
fainting
dizziness
somnolence
nasal congestion
abnormal ejaculation
Q18: administration time for tamsulosin/terazosin/doxazosin
A: given in morning
Q19: patient education for tamsulosin/terazosin/doxazosin
A: monitor for signs of hypotension
dilation of eyes may be difficult
Iowa | UPDATED Questions with 100% Verified Answers
Q1: medications used for gallbladder disease
A: ursodeoxycholic acid (UDCA)/chenodeoxycholic acid (chenodiol or CDCA)
mono-octanoin/metyhl tertiary butyl ether
Q2: how long is therapy with ursodeoxycholic
acid/chenodeoxycholic acid require?
A: 6-12 months of therapy required
Q3: MOA for ursodeoxycholic acid/chenodeoxycholic acid
A: reduce the size or dissolve small gallstones
prevents more gallstones from occuring
Q4: what patients are NOT canidates for ursodeoxycholic
acid/chenodeoxycholic acid therapy?
A: with frequent symptoms
cystic duct occlusion
pigment stones
Q5: MOA for mono-octanoin/methyl tertiary butyl ether
A: dissolved gallstones
Q6: how is mono-octanoin administered?
A: infused through percutaneous tube directly into gallbladder
ERCP
Q7: MOA for creon
A: pancreatic enzyme to aid in digestion
Q8: what is creon used as a therapy for?
A: imbalanced nutrition diagnosis for chronic pancreatitis
Q9: role of octredotide/vasopressin for liver failure
A: treatment for decreased cardiac output
Q10: role of rifaximin and lactulose for liver failure
A: ammonia-lowering agents
treatment of hepatic encephalopathy
, Q11: patient education for rifaximin and lactulose
A: want 3 stools per day
avoid GI bleeding
decrease protein
Q12: when giving rifaxamin and lactulose, what do you want to
monitor for?
A: monitor daily ammonia and BMP
to monitor changes in enzymes
Q13: medications used for urinary retention
A: tamsulosin (selective)
terazosin/doxazosin (non-selective)
bethanechol
Q14: medications used for urinary incontinence
A: oxybutynin
tolterodine
Q15: MOA for tamsulosin (selective)
A: blocks alpha1-receptors ONLY IN BLADDER
relaxes smooth muscle in bladder neck and prostate capsule
Q16: MOA for terazosin/doxazosin (non-selective)
A: blocks alpha1-receptors IN WHOLE BODY
relaxes smooth muscle in bladder neck and prostate capsule
Q17: adverse effects for tamsulosin/terazosin/doxazosin
A: MAINLY WITH NON-SELECTIVE
hypotension
fainting
dizziness
somnolence
nasal congestion
abnormal ejaculation
Q18: administration time for tamsulosin/terazosin/doxazosin
A: given in morning
Q19: patient education for tamsulosin/terazosin/doxazosin
A: monitor for signs of hypotension
dilation of eyes may be difficult
